NHLBI Catalyze Program: Transforming basic scientific discoveries into viable therapeutics, devices, and diagnostics to treat heart, lung, blood, and sleep diseases and disorders
  • Drives development of new potential heart, lung, blood, and sleep (HLBS)-related therapies and cures by supporting early product definition studies and safety testing
  • Supports development of novel, enabling platform technologies that catalyze next-generation, predictive, diagnostic, and therapeutic products

Funding

Unique funding strategy to leverage federal investment with matching commitments and flexibility to adjust to technical challenges

Coordinated Approach

A seamless continuum of programs to advance promising HLBS-related technologies from validation to first-in-human trials

Individualized Support

Milestone-driven project management and support to mitigate technical risk

Program Flexibility

Evaluation and oversight to adjust the program based on trends and challenges, and to share best practices

The Catalyze Program provides a bridge from basic research to clinical research across the entire heart, lung, blood, and sleep research spectrum, and trains a diverse scientific workforce fluent in product development and entrepreneurship.

Recent webinars

See more events

Submit your email address so that we can contact you with Catalyze updates:

Thanks for subscribing!
Unable to subscribe. Please try again later.

Catalyze was established by the National Heart, Lung, and Blood Institute (NHLBI) within the National Institutes of Health (NIH).

This research was, in part, funded by the National Institutes of Health (NIH) Agreement OT2 HL157844-01. The views and conclusions contained in this document are those of the authors and should not be interpreted as representing the official policies, either expressed or implied, of the NIH.